

dysfunction [21, 22], dependence or abuse [23-27], obesity [28], marked drowsiness (sometimes loss of consciousness), and an expensive drug price. Two short-term studies reported cognitive dysfunction [21, 22] due to pregabalin. Cognitive dysfunction may continue for a long time. It is almost impossible to detect long-lasting cognitive dysfunction at the individual patient level. It is unknown whether long-lasting cognitive dysfunction improves U Yf the

3. Pang WK, Yeter KC, Torralba KD, Spencer HJ, Khan NA (2015) Financial Web [W] of interest and their association with outcome and quality of V[er]ba n[on] [U]drug therapy randomized controlled trials. *Int J Rheum Dis* 18: 606-615
4. Bekelman JE, Li Y, Gross CP (2003) Scope and impact of b[io]b[io] Web [W] of interest in biomedical research: a systematic review. *JAMA* 289: 454-465
5. Sismondo S (2008) Pharmaceutical company funding and its consequences: a qualitative systematic review. *Contemp Clin Trials* 29: 109-113
6. Cosgrove L, Shi L, Creasey DE, Anaya-McKivergan M, Myers JA, et al. (2011) Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' b[io]b[io] associations with industry. *PLOS One* 6: e18210
7. Sinyor M, GWU Yf A, Smart KA, Levitt AJ, Lancot KL, et al. (2012) Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials. *J Clin Psychiatry* 73: e277-287
8. Becker JE, Krumholz HM, Ben-Josef G, Ross JS (2014) Reporting of results in ClinicalTrials.gov and high-impact journals. *JAMA* 311: 1063-1065
9. Ebrahim S, Bance S, Athale A, Malachowski C, Ioannidis JP (2016) Meta-analyses with industry involvement are massively published and report no caveats for antidepressants. *J Clin Epidemiol* 70: 155-163
10. Reda JM (2010) New and emerging therapeutic agents for the treatment of V[er]ba n[on] [U] an update. *J Pain Res* 3: 89-103
11. Straube S, Derry S, Moore RA, McQuay HJ (2010) Pregabalin in V[er]ba n[on] [U] meta-analysis of Y [W] and safety from company clinical trial reports. *Rheumatology (Oxford)* 49: 706-715
12. Tzellos TG, Toulis KA, Goulis DG, Papazisis G, Zampeli VA, et al. (2010) Gabapentin and pregabalin in the treatment of V[er]ba n[on] [U] a systematic review and a meta-analysis. *J Clin Pharm Yf* 35: 639-656
13. Hauser W, Petzke F, Sommer C (2010) Comparative Y [W] and harms of duloxetine, milnacipran, and pregabalin in V[er]ba n[on] [U] syndrome. *J Pain* 11: 505-521
14. Choy E, Marshall D, Gabriel ZL, Mitchell SA, Gylee E, et al. (2011) A systematic review and mixed treatment comparison of the Y [W] of pharmacological treatments for V[er]ba n[on] [U] Semin Arthritis Rheum 41: 335-345
15. Hauser W, Bernardy K, Uceyler N, Sommer C (2009) Treatment of V[er]ba n[on] [U] syndrome with gabapentin and pregabalin - a meta-analysis of randomized controlled trials. *Pain* 145: 69-81
16. Keshavarz K, Hashemi-Meshkini A, Gharibnaseri Z, Nikfar S, Kebriaeezadeh A, et al. (2013) A systematic W[ork] Y [W] Y [W] analysis of pregabalin in the management of V[er]ba n[on] [U] an Iranian experience. *Arch Med Sci* 9: 961-967
17. Derry S, Cording M, K [] Yb PJ, Law S, Phillips T, et al. (2016) Pregabalin for pain in V[er]ba n[on] [U] in adults. *Cochrane Database Syst Rev* 9: CD011780
18. Ney JP, Devine EB, Watanabe JH, Sullivan SD (2013) Comparative Y [W] of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons. *Pain Med* 14: 706-719
19. Darba J, Kaskens L, Perez C, Alvarez E, Navarro-Artieda R, et al. (2014) Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. *Adv Yf* 31: 1-29
20. Perez C, Latymer M, Almas M, Ortiz M, Clair A, et al. (2017) Does Duration of Neuropathic Pain Impact the 9 Y [W] Y [W] of Pregabalin? *Pain Pract* 17: 470-479
21. Salinsky M, Storzbad D, Munoz S (2010) Cognitive Y [W] of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. *Neurology* 74: 755-761
22. Sanderson C, Quinn SJ, Agar M, Chye R, Clark K, et al. (2016) Pharmacovigilance in hospice/palliative care: net Y [W] of pregabalin for neuropathic pain. *BMJ Support Palliat Care* 6: 323-330
23. Schjerming O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J (2016) Abuse potential of pregabalin: a systematic review. *CNS Drugs* 30: 9-20

Citation:

it does Not Necessarily AgreeeeeeMnhr.din.lgltermaioü

42. D gMfa YgMf B, Tumena T, Gassmann KG, Maas R, Fromm MF (2017) Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients. *PLoS One* 12: e0171353
43. Kessing LV, Sondergaard L, Forman JL, Andersen PK (2009) Antidepressants and dementia. *J Psychiatr Disord* 117: 24-29
44. Oh SW, Kim J, Myung SK, Hwang SS, Yoon DH (2014) Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies. *Br J Clin Pharmacol* 78: 727-737.
45. Ray WA, Meredith S, Udell PB, Hall K, Murray KT (2004) Cyclic antidepressants and the risk of sudden cardiac death. *Clin Pharmacol Ther* 75: 234-241.
46. Nishishinya B, Urrutia G, Walitt B, Rodriguez A, Gochhayat N, et al. (2008) Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. *Rheumatology (Oxford)* 47: 1741-1746
47. Rico-Villademoros F, Slim M, Calandre EP (2015) Amitriptyline for the treatment of fibromyalgia: a comprehensive review. *Expert Rev Neurother* 15: 1123-1150.
48. Moore RA, Derry S, Aldington D, Cole P, Kalso G, et al. (2015) Amitriptyline for neuropathic pain in adults. *Cochrane Database Syst Rev* 7: CD008242.
49. Sanchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. *Cell Mol Neurobiol* 19: 467-489.
50. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, et al. (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. *Pain* 132: 237-251.